12.2 Nitrous Oxide Inhalation Sedation & Intravenous Sedation Guidelines

12.2 Nitrous Oxide Inhalation Sedation & Intravenous Sedation Guidelines

Conscious sedation techniques play a vital role in contemporary Australian dentistry by alleviating anxiety, raising pain thresholds, and facilitating complex operative care for phobic or medically compromised patients. In Australia, the administration of conscious sedation is strictly regulated by the Dental Board of Australia (DBA) registration standards and guidelines jointly formulated with the Australian and New Zealand College of Anaesthetists (ANZCA) (specifically ANZCA Professional Document PS09: Guidelines on Sedation and/or Analgesia for Diagnostic Interventional Medical, Dental or Surgical Procedures). Candidates preparing for the ADC Written Examination must demonstrate thorough knowledge of sedation pharmacology, administration protocols, absolute contraindications, physiological monitoring, and emergency management.

---

1. Pharmacology & Physiology of Nitrous Oxide ($N_2O$)

Nitrous oxide is an inorganic, non-irritating, colorless gas with a sweet odor. When co-administered with oxygen ($O_2$), it produces relative analgesia, anxiolysis, and mild sedation without loss of consciousness when administered correctly.

• Mechanism of Action: $N_2O$ acts as a central nervous system depressant. Its analgesic effects are mediated via the release of endogenous opioids acting on $\mu$-opioid receptors and modulation of descending noradrenergic pathways. Its anxiolytic effects stem from $\text{GABA}_A$ receptor facilitation via the benzodiazepine binding site, while its anaesthetic actions involve non-competitive inhibition of N-methyl-D-aspartate (NMDA) glutamate receptors.
• Potency & Solubility:
  • Minimum Alveolar Concentration (MAC): $N_2O$ has a MAC of 104%, meaning it is a low-potency agent incapable of producing surgical general anaesthesia on its own at normal atmospheric pressure.
  • Blood-Gas Partition Coefficient: 0.47. This extremely low solubility in blood accounts for its exceptionally rapid induction (onset within 2–3 minutes) and rapid clinical recovery upon discontinuation.
• Concentration Effect & Second Gas Effect: High concentrations of $N_2O$ accelerate the arterial pressure rise of both $N_2O$ itself (concentration effect) and companion volatile anaesthetics co-administered during general anaesthesia (second gas effect).

Diffusion Hypoxia (Fink Effect)

At the end of a nitrous oxide procedure, when $N_2O$ delivery is abruptly stopped and the patient breathes room air, $N_2O$ rapidly diffuses out of the blood plasma down its concentration gradient into the pulmonary alveoli. Because of its high volume and low solubility, huge quantities of $N_2O$ flood the alveolar space, displacing and diluting alveolar oxygen ($O_2$) and carbon dioxide ($CO_2$). This drop in alveolar partial pressure of oxygen ($PAO_2$) causes transient arterial hypoxia, headache, dizziness, and nausea.

• Mandatory Prevention Protocol: Clinicians must administer 100% oxygen ($O_2$) for 3 to 5 minutes at the conclusion of every $N_2O/O_2$ inhalation sedation session to flush $N_2O$ from the lungs and prevent diffusion hypoxia.

---

2. Clinical Administration Protocol: Incremental Titration

Nitrous oxide must always be administered using a dedicated relative analgesia (RA) machine equipped with safety features: a fail-safe mechanism (which automatically shuts off $N_2O$ flow if $O_2$ pressure drops below 30 psi), an air-entrainment valve, an oxygen flush button, and a minimum delivery concentration of 30% $O_2$ (preventing delivery of hypoxic gas mixtures <30% $O_2$).

Step-by-Step Titration Technique

1. Pre-Sedation Health Check: Verify medical history, baseline vital signs (blood pressure, pulse, oxygen saturation $SpO_2$), and informed consent.
2. Establish Minute Volume (100% $O_2$): Place the nasal hood and adjust flow rate with 100% $O_2$ for 2 to 3 minutes to establish the patient's individual minute volume (typically 5 to 7 L/min for adults, 3 to 5 L/min for children).
3. Incremental Titration: Introduce $N_2O$ at 10% to 20% and increase in 10% increments every 60 to 90 seconds, while reducing $O_2$ flow proportionately to maintain constant total volume.
4. Maintenance Phase: The ideal therapeutic sedation level is achieved in most patients at 30% to 50% $N_2O$ (with 50% to 70% $O_2$). Note: The concentration of $N_2O$ should never exceed 70% in dental relative analgesia.
5. Completion & Post-Oxygenation: Turn off $N_2O$ flow completely and deliver 100% $O_2$ for 3–5 minutes.

Clinical Presentation: Ideal Sedation vs. Over-Sedation

---

3. Absolute & Relative Contraindications for $N_2O/O_2$ Sedation

Nitrous oxide diffuses readily into closed, air-filled body cavities, causing rapid expansion of gas volume and elevation of intra-cavity pressure. This physical characteristic dictates critical clinical contraindications:

A. Absolute Contraindications

1. First Trimester of Pregnancy: $N_2O$ inactivates methionine synthase via oxidation of cobalt in vitamin B12, disrupting DNA synthesis and folate metabolism; potential teratogenic and abortifacient risk.
2. Middle Ear Surgery / Acute Otitis Media / Tympanic Membrane Graft: Gas expansion causes tympanic membrane rupture or graft displacement.
3. Pneumothorax / Pulmonary Emphysema / Severe Bullous COPD: $N_2O$ expands bullae or pneumothorax, causing lung collapse and tension pneumothorax.
4. Bowel Obstruction / Acute Abdomen: Expansion of intestinal gas loops causing bowel perforation.
5. Recent Intraocular Gas Injection: Patients who have undergone vitreoretinal surgery with intraocular gas tamponade (e.g., perfluoropropane $C_3F_8$ or sulfur hexafluoride $SF_6$ gas bubble within the past 3 months). $N_2O$ diffusion causes massive intraocular pressure elevation, leading to retinal artery occlusion and permanent blindness.

B. Relative Contraindications

• Upper respiratory tract infection or severe nasal congestion (inability to breathe through nose).
• Severe psychiatric disorders or personality disorders (risk of paradoxical agitation or loss of emotional control).
• Bleomycin chemotherapy history (increased pulmonary toxicity risk).
• Severe mouth breathers or uncooperative paediatric patients.

---

4. Intravenous Conscious Sedation Guidelines (ANZCA PS09 & DBA)

Intravenous (IV) sedation involves the administration of central nervous system depressants via the parenteral route to achieve moderate sedation. Under DBA Registration Standards, dentists administering IV sedation must hold endorsed registration in conscious sedation following accredited post-graduate training.

Continuum of Sedation Depth

• Minimal Sedation (Anxiolysis): Normal response to verbal commands; airway and cardiovascular function unaffected.
• Moderate Sedation (Conscious Sedation): Purposeful response to verbal commands or light tactile stimulation; spontaneous ventilation adequate; protective airway reflexes fully maintained; no airway intervention required.
• Deep Sedation: Purposeful response only following painful stimulation; airway support may be required; partial loss of protective reflexes.
• General Anaesthesia: Unarousable loss of consciousness; impairment of ventilatory function; mandatory artificial airway support.

Pharmacological Agents & Emergency Reversal

• Midazolam: Short-acting water-soluble benzodiazepine. Dose titrated slowly in 1.0 to 2.0 mg IV increments over 1–2 minutes, assessing clinical effect before administering further doses (typical adult total dose: 2.5 to 7.5 mg).
  • Mechanism: Enhances $\text{GABA}_A$ receptor inhibitory transmission.
  • Specific Reversal Agent: Flumazenil (competitive benzodiazepine receptor antagonist). Administered IV in 200 mcg increments every 60 seconds (up to maximum 1.0 mg) in cases of accidental over-sedation or respiratory depression.
• Propofol: Rapid-acting hypnotic used in targeted-controlled infusion (TCI) IV sedation by endorsed practitioners or specialist anaesthetists.

Pre-Operative Fasting & Emergency Preparedness

According to ANZCA guidelines, patients undergoing IV sedation should comply with standard pre-operative fasting rules (2 hours for clear fluids, 6 hours for solids and milk). Continuous electro-cardio monitoring, pulse oximetry ($SpO_2$), non-invasive blood pressure (NIBP), and capnography (end-tidal $CO_2$) are mandatory. Emergency drugs (Adrenaline, Atropine, Flumazenil, Naloxone) and positive-pressure oxygen resuscitation equipment (bag-valve-mask, laryngeal mask airways, suction) must be verified immediately prior to initiating sedation.